The company has been developing several ways of delivering the powder, including as a sachet, tablet, or in dairy products. According to the company's research the chewable and soluble formats have shown the greatest potential because they would be easier to market. Alltracel's bioactive is aimed at lowering LDL cholesterol, reducing blood glucose levels and helping to prevent arterial plaque build up. At the moment it is not available on the market but Alltracel says it is working with potential partners to bring the bioactive as either an ingredient or finished product. A clinical trial is also underway to test and refine the final products format and the group said yesterday it is looking to gain regulatory approval for the cellulose technology. A company spokesperson told NutraIngredients.com that the firm hoped to know which market and indeed what type of product it would release the bioactive as by the end of the year. The firm is in negotiations with a North American firm with the aim to market the cellulose ingredient globally as a range of functional foods. In April Alltracel reported a watershed financial year 2006 in which it generated profit for the first time, which put it in a strong position for introduction of cardiovascular and cosmeceutical products. The Irish biotech reported operating profit of €315,000 for the year ended December 31 2006, compared to an operating loss of €1.7m in 2005. Revenues to date have spun from the company's oral care and wound care technologies; in the last year it saw its first license revenue from its patented Nanofibre technology, through its new subsidiary, Nanopeutics. As part of the group's annual general meeting update, Alltracel chief executive Tony Richardson said: "2007 to date has delivered solid trading and continued technology and commercial breakthroughs and we remain confident of continued profitability improvements for the full year 2007. "These recent significant technology breakthroughs from product testing and trial work across our divisions with partners along with our ongoing partner development work in the cosmeceuticals and cardiovascular health sectors have presented Alltracel with another efficient and profitable revenue opportunity which are now moving to capture through the establishment of Alltracel Healthcare Services (AHS)." Richardson added that AHS will provide scientific research, clinical trial and development services for a whole range of health care companies, as well as providing in house trial, testing and laboratory services.